Biographical Sketches of Course Directors and Presenting
Faculty (M - Z)
Bios A-L
HUSSEINI K. MANJI, M.D., F.R.C.P.C.
Chief, Laboratory of Laboratory of Molecular
Pathophysiology, NIMH
Visiting Professor Department of Psychiatry,
Columbia University College Physicians & Surgeons.
Dr. Manji received his B.S. (Biochemistry) and M.D.
from the University of British Columbia. Following psychiatry residency
training, he completed fellowship training in psychopharmacology at the NIMH and
undertook extensive additional training in Cellular and Molecular Biology at the
NIDDK. The major focus of his ongoing research is the investigation of disease-
and treatment-induced changes in gene and protein expression profiles that
regulate neuroplasticity and cellular resilience in mood disorders. In broad
terms, his laboratories’ scientific goals are to capitalize upon recent insights
into our understanding of the signaling pathways mediating the effects of mood
stabilizers, in order to understand the pathophysiology of severe mood disorders
and to develop improved therapeutics. He has received ongoing research funding
from the NIH, Private Foundations, and pharmaceutical industry for his work on
signaling pathways, gene expression and new medication development for severe
mood disorders. Dr. Manji is a previous recipient of the A. E. Bennett Award for
Neuropsychiatric Research, the Ziskind-Somerfeld Award for Neuropsychiatric
Research, the NARSAD Mood Disorders Prize (Nola Maddox Falcone Prize), the
Mogens Schou Distinguished Research Award, the ACNP Joel Elkes Distinguished
Research Award, the NIMH award for excellence in clinical care and research, the
NIMH Outstanding Mentor award, the NIMH Supervisor of the Year Award, the
Canadian Association of Professors in Psychiatry Award, and a Visiting Professor
lectureship to the Salpetreire Hospital, Paris. He has published extensively on
the molecular and cellular mechanisms of action of mood-stabilizing agents, and
has edited a book on the mechanisms of action of antibipolar treatments. He is a
councilor for the Collegium Internationale neuro-psychopharmacologicum (CINP), a
member of the Canadian College of Neuropsychopharmacology, a fellow of the
American College of Neuropsychopharmacology (ACNP), and chairs the ACNP’s Task
Force on New Medication Development. He is currently sits on the NIMH Bipolar
Initiative Scientific Advisory Board, is a member of the National Alliance for
Research in Schizophrenia and Affective Disorders (NARSAD) Scientific Advisory
Committee, National Alliance for the Mentally Ill (NAMI) Center on Practice &
Research Advisory Committee, the Child and Adolescent Bipolar Foundation
Professional Advisory Council, the Scientific Advisory Board of the Juvenile
Bipolar Research Foundation and the Stanley Medical Research Institute
Scientific Advisory Board. Dr. Manji has also served as a member of the National
Board of Medical Examiners Behavioral Science Test Committee, and the USMLE Step
1 Test Material Development Committee for Behavioral Science, and is the
Director of the NIH Foundation for the Advanced Education in the Sciences
Graduate Course in the Neurobiology of Mental Illness, co-chair, of the
preclinical models workgroup of the NIMH Strategic Plan for mood disorders, and
member of the NIH’s Roadmap initiative for multi-disciplinary research. Dr.
Manji is currently editor of Neuroscience Perspectives, Biological Psychiatry,
associate editor of the journal Bipolar Disorders, and sits on the Editorial
Board of the official journal of the CINP.
LAUREN B. MARANGELL, M.D.
Brown Foundation Chair, Psychopharmacology of Mood
Disorders,
Department of Psychiatry
Baylor College of Medicine
Houston, Texas
Lauren B. Marangell, MD, is the Brown Foundation
Chair of the Psychopharmacology of Mood Disorders in the Department of
Psychiatry at Baylor College of Medicine in Houston, Texas, where she is the
Director of Mood Disorders Research. Following her residency, she spent three
years at the National Institute of Mental Health as a Fellow and Senior Staff
Fellow specializing in clinical research, psychopharmacology, and mood
disorders. Dr. Marangell has received numerous awards, including the Laughlin
Fellowship of the American College of Psychiatrists, the Young Investigators
Award from the National Alliance for Research in Schizophrenia and Affective
Disorders, the Exemplary Psychiatrist Award from the National Alliance for the
Mentally Ill, and the McKnight Neuroscience of Brain Disorders Award. In
addition to contributing to the scientific literature, she is lead author of the
Concise Guide to Psychopharmacology, published in 3 languages by The American
Psychiatric Press, Inc.
SUSAN L. McELROY,
M.D.
Professor of Psychiatry and Neuroscience
University of Cincinnati College of Medicine
Cincinnati, Ohio
Susan L. McElroy, MD, is Professor of Psychiatry and
Neuroscience at the University of Cincinnati College of Medicine in Ohio. In
addition, she is the Senior Consulting Psychiatrist at the Ohio Department of
Mental Health at the Lewis Center in Cincinnati.
Dr. McElroy earned her BA at Colgate University in
Hamilton, New York, and her MD at Cornell University Medical College, New York.
After graduating she completed her internship in internal medicine at Columbia
Presbyterian Hospital, New York, and her residency in psychiatry at McLean
Hospital in Belmont, Maryland.
Dr. McElroy is a member of the Scientific Advisory
Board for the National Depressive and Manic Depressive Association, and the
Depression and Bipolar Support Alliance (Ohio Chapter and Cincinnati Chapter).
She is a long-time member of the American Psychiatric Association, currently
serving on the APA Corresponding Committee on Research on Psychiatric
Treatments. Dr. McElroy also serves as a reviewer for many journals, including
the Journal of Clinical Psychiatry, JAMA, and Archives of General Psychiatry.
In addition, she sits on the editorial board for many journals, including the
Journal of Clinical Psychiatry, the Journal of Psychotic Disorders, and the
Journal of Bipolar Disorders.
Dr. McElroy is the co-investigator on several
research projects, including “A Prospective Study of Glucose Tolerance in New
Onset Psychotic and Bipolar Disorder,” which is funded by the American Diabetes
Association, and “Impulsivity as a Core Trait of Bipolar Disorder,” which is
funded by the National Institute of Mental Health. She has published more than
200 articles, more than 100 book reviews/chapters, and more than 90 abstracts.
Her work has appeared in the American Journal of Psychiatry, Archives of General
Psychiatry, the Journal of Affective Disorders, and the Journal of Clinical
Psychiatry.
KATHLEEN
MERIKANGAS, PH.D.
Senior Investigator Intramural Research
Chief, Section on Developmental Genetic Epidemiology
Mood and Anxiety Disorders Program
National Institute of Mental Health
Dr. Kathleen Merikangas is a senior investigator in
the Intramural Research Program, where she is Chief of the Section on
Developmental Genetic Epidemiology in the Mood and Anxiety Disorders Program.
Prior to joining the Intramural Program at the NIMH, Dr. Merikangas was
Professor of Epidemiology and Public Health, Psychiatry and Psychology at the
Yale University School of Medicine.
Dr. Merikangas received a B.A., summa cum laude, in
experimental psychology and music from the University of Notre Dame. She
completed her Master’s degree training and internship in clinical psychiatry at
the Western Psychiatric Institute and Clinic at the University of Pittsburgh
School of Medicine, followed by doctoral training in chronic disease
epidemiology at the University of Pittsburgh School of Public Health. She
received a Research Scientist Development Award from the National Institute of
Mental Health to pursue post-doctoral training in genetic epidemiology at the
Yale University School of Medicine.
She is an author of more than 200 scientific
publications and has presented lectures throughout the U.S. and in more than 20
countries. She is on the Editorial Board of several scientific journals and has
been on the scientific advisory boards of numerous organizations and academic
institutions.
Dr. Merikangas has been actively engaged in genetic
epidemiologic research for more than 15 years. She has been the principal
investigator, co-investigator or consultant to numerous federally and
non-federally funded research grants. The major areas of her research are: (1)
studies of the patterns and components of familial aggregation of mental
disorders and familial mechanisms for comorbidity of mental and medical
disorders; (2) identification of early signs and risk factors for psychiatric
disorders among high and low risk youth using prospective longitudinal high risk
studies; and (3) large scale population based studies of mental disorders
including high risk designs and prospective longitudinal research.
At the NIMH, the major project underway in her
research group is a community-based family study of affective spectrum disorders
and their overlap with other mental disorders, especially anxiety disorders and
medical disorders such as migraine and cardiovascular disease. The goal of this
research is to identify the familial clustering of components of mood disorders
and migraine and endophenotypes that are closer to the biologic expression of
genes underlying these disorders as well as environmental moderators of genetic
expression.
Currently, Dr. Merikangas is also co-investigator of
the National Comorbidity Survey-Replication (NCS-R), a large-scale epidemiologic
study of mental disorders in the U.S. and several international sites directed
by Dr. Ronald Kessler and funded by the National Institute of Mental Health.
She is coordinating the extension of the National Comorbidity Study in the U.S.
to include youth ages 12 – 18. As part of the W.H.O. Health 2000 initiative,
estimates of morbidity of mental disorders will be collected from 20 countries.
In addition to her research, Dr. Merikangas plays a
key role in training, having taught formal course work in psychiatric
epidemiology and genetic epidemiology at Yale University for several years,
directing a training program in psychiatric epidemiology, and serving as the
primary mentor of more than 40 pre-and post-doctoral fellows. She has recently
developed a joint training program between the National Institute of Mental
Health Intramural Research Program and the Johns Hopkins University, Bloomberg
School of Public Health and Medicine, to provide training to scientists
interested in neuropsychiatric genetics.
DAVID J.
MIKLOWITZ, PH.D.
Professor of Psychology and Psychiatry
Departments of Psychology and Psychiatry
University of Colorado
Boulder CO, USA
Dr. Miklowitz is Professor of Psychology and
Psychiatry at the University of Colorado (Boulder and Health Sciences Center
Campuses). He completed his undergraduate work at Brandeis University and his
doctoral (1979-1985) and postdoctoral (1985-1988) work at UCLA. His research
focuses on family environmental factors and family psychoeducational treatments
for adult-onset and childhood-onset bipolar disorder.
Dr. Miklowitz has received the Joseph Gengerelli
Dissertation Award from UCLA (1986), Young Investigator Awards from the
International Congress on Schizophrenia Research (1987) and the National
Alliance for Research on Schizophrenia and Depression (NARSAD; 1987), a Research
Faculty Award from the University of Colorado (1998), and a Distinguished
Investigator Award from NARSAD (2001). He has received funding for his research
from the National Institute of Mental Health, the John D. and Catherine T.
MacArthur Foundation, and the Robert Sutherland Foundation.
Dr. Miklowitz has published more than 120 research
articles and book chapters on bipolar disorder and schizophrenia. His articles
have appeared in the Archives of General Psychiatry, the American Journal of
Psychiatry, the British Journal of Psychiatry, the Journal of Nervous and Mental
Disease, Biological Psychiatry, the Journal of Consulting and Clinical
Psychology, and the Journal of Abnormal Psychology. His book with Michael
Goldstein, Bipolar Disorder: A Family-Focused Treatment Approach (Guilford), won
the 1998 Outstanding Research Publication Award from the American Association
for Marital and Family Therapy. His latest book, also with Guilford, is titled
The Bipolar Disorder Survival Guide
PHILIP B. MITCHELL, MD, FRANZCP, FRCPsych
Professor and Head, School of Psychiatry,
University of New South Wales,
Sydney, Australia
Professor Mitchell received his undergraduate
medical training at the University of Sydney, graduating with first class
honours in 1976. He undertook training in psychiatry from 1979 to 1984, during
which time he worked in both Sydney (Prince Henry and Prince of Wales Hospitals;
and Westmead Hospital) and London (the Royal Bethlem and Maudsley Hospitals; and
St. Georges Hospital). In 1985 he commenced academic life as a lecturer at the
University of New South Wales (UNSW) in Sydney. He was awarded his research
doctorate (MD) in 1991 for studies on the neuroendocrinology of depression. In
1993 he worked as a visiting researcher in psychopharmacology at NIMH. He was
promoted to full professor in 1998, and appointed Head of the School of
Psychiatry at UNSW in 2002. He is also a consultant psychiatrist at the Black
Dog Institute in Sydney, and Convenor of Brain Sciences UNSW (a cross-faculty
and institute research consortium in neuroscience, psychiatry, psychology and
neurology).
Professor Mitchell’s original research focus was on
neuroendocrine and monoamine responses to challenges with clonidine and
fenfluramine as indices of central neurotransmitter function in depression. He
still continues studies in unipolar depression, with his recent major work being
in gene-environment interactions in the onset of depression, transcranial
magnetic stimulation (rTMS) as a potential treatment for depression, and the
changing pattern of antidepressant prescribing (particularly the relationship of
that with suicide rates).
Over the last 10-15 years, his main research
emphasis has moved to bipolar disorder with particular interests in molecular
genetics, phenomenology of bipolar depression, pharmacological and psychological
treatments, and epidemiology. In 2001, in conjunction with Dr Gin Malhi, he
established a specialized clinical research bipolar disorders clinic in Sydney.
Professor Mitchell was awarded the Organon Senior
Research Award of the Royal Australian and New Zealand College of Psychiatrists
in 2002, and the Founders Medal of the Australasian Society for Psychiatric
Research in 2004. In conjunction with colleagues, he has published more than
300 articles and book chapters. He is on the editorial boards of the Australian
and New Zealand Journal of Psychiatry, Psychiatric Genetics and CNS Drugs.
He is Chair of the Corresponding Organisations
Committee of CINP; and a member of the ISBD Diagnostic Guidelines Committee,
chairing the working party on bipolar depression diagnosis. He has recently
been appointed chair of the New South Wales Mental Health Priority Taskforce,
and is a member of the NSW Health Care Advisory Council.
BRUNO
MÜLLER-OERLINGHAUSEN, DR. MED.
Professor em. of Clinical Psychopharmacology
Freie Universität Berlin (Germany)
Chairman of the Drug Commission of the German
Medical Association
Bruno Müller-Oerlinghausen was born in 1936 in
Berlin. He obtained his training in medicine at the universities of Göttingen,
Munich, Francfort/M., Freiburg, and Berlin (West). 1964 to 1969 he underwent a
postgraduate training in pharmacology and toxicology at the Department of
Pharmacology, University of Goettingen, and qualified as a lecturer in
pharmacology and toxicology with a thesis on “Hormonal influence on mechanisms
of hepatic detoxification”. 1969 to 1971 he was assigned to the Department of
Medical Sciences (Ministry of Public Health) in Bangkok (Thailand) by the
government of the Federal Republic of Germany as an expert in pharmacology. He
built up a pharmacological research lab and trained the Thai staff in methods to
investigate the pharmacology of old-style herbal medicine. In 1971 he entered
the Department of Psychiatry, Freie Universität Berlin, for additional training
in clinical psychiatry, and in 1974 he was appointed as Chief Scientist of the
Lithium Clinic Berlin, and at the same time promoted to Professor of Clinical
Psychopharmacology and Chief of the Laboratory of Clinical Psychopharmacology.
For 27 years he was editor-in-chief of Pharmacopsychiatry, and he is associate
editor of many other journals, such as Bipolar Disorders, Journal of Psychiatry
and Neuroscience, or Drug Research. 1983 to 1987 he was elected as president of
AGNP (Association for Neuropharmacology of the German speaking countries), 1982
to 1988 he served as Councillor of the Executive Board of CINP. Since 1994 he is
the acting chairman of the Drug Commission of the German Medical Association.
His scientific interests were mainly related to the
clinical pharmacology of antidepressants, neuroleptics and particularly lithium
salts in humans. Recent work focused on long-term effects of lithium salts with
special regard to its serotonergic action including anti-aggressive and
antisuicidal effects; serotonergic mechanisms in patients with affective
disorders; genetic studies in depression and in clozapine-induced
agranulocytosis.
BENOIT H. MULSANT,
M.D.
Professor of Psychiatry
University of Pittsburgh School of Medicine
Associate Director, Geriatric Fellowship Program
Medical Director, Electroconvulsive Therapy Service
Western Psychiatry Institute and Clinic
Pittsburgh, Pennsylvania
Dr. Mulsant is currently a Professor of Psychiatry
at the School of Medicine, University of Pittsburgh. He is also the Associate
Director of the Geriatric Psychiatry Fellowship Program and the Medical Director
of the Electroconvulsive Therapy Service at Western Psychiatric Institute and
Clinic, University of Pittsburgh Medical Center. Dr. Mulsant has authored and
co-authored more than 200 journal articles and book chapters and he has been
listed in The Best Doctors in America since 1996. He has been and is currently
a principal investigator for several federally-funded and industry-sponsored
clinical research trials on psychiatric disorders in geriatric patients. Dr.
Mulsant earned his MD from the School of Medicine, Laval University, Quebec; he
completed his internship in internal medicine and neurology at Royal Victoria
Hospital, Montreal, and Montreal Neurological Hospital, and his residency in
psychiatry at Western Psychiatric Institute and Clinic, University of
Pittsburgh. He is a Diplomate in Psychiatry, American Board of Psychiatry and
Neurology, with added qualifications in Geriatric Psychiatry, as well as a
member of the American Association for Geriatric Psychiatry, the American
Psychiatric Association, the American College of Psychiatrists, and a founding
member of the International College of Geriatric Psychoneuropharmacology. He is
a member of the Geriatric Psychiatry Committee of the American Board of
Psychiatry and Neurology and he serves on the editorial board of the American
Journal of Geriatric Psychiatry; he is also a reviewer for numerous academic
journals, including the Journal of the American Medical Association, American
Journal of Psychiatry, Journal of American Geriatrics Society, and the
International Journal of Geriatric Psychiatry.
ROBIN MURRAY, M.D.
Dean of the Institute of Psychiatry
Professor of Psychiatry
University of Glasgow, Scotland
Robin Murray received his medical degree from the
University of Glasgow, Scotland, and trained in Internal Medicine there. He
then came to study psychiatry at the Maudsley Hospital in London and has
remained there ever since, apart from 1 year as MRC Fellow at NIH in
Washington. He was Dean of the Institute of Psychiatry and is now Professor of
Psychiatry there; he tries, not always successfully, to avoid drowning in
University Committees. According to ESI ScienceWatch, he was the most widely
cited schizophrenia researcher in the decade, 1991-2000. His special interest is
in the understanding and treatment of psychotic illnesses, and he runs a
clinical team for people with these illnesses.
WILLEM A. NOLEN,
MD, PhD
Professor of Psychiatry
University of Groningen Medical Centre
The Netherlands
Willem A. Nolen (1948) studied medicine at the
University of Leiden, and was trained in psychiatry (1974-1978) at Psychiatric
Centre Bloemendaal (nowadays Parnassia), The Hague.
From 1978-1993 he was appointed at Bloemendaal, The
Hague, including 10 years as head of the internal residence training. From
1993-2003 he was appointed at the H.C. Rümke Group (nowadays Altrecht Institute
for Mental Health Care) in Utrecht. From 1999-2004 he was also part-time
Professor in psychiatry and psychopharmacology at the University Medical Center
Utrecht. In Utrecht he has been principle investigator of the Utrecht site of
the international Stanley Foundation Bipolar Network (1996-2002) and of the
Stanley International research Center (2000-2003)
Since 2003 he is affiliated at the University of
Groningen Medical Centre, and since 2004 full-time Professor of psychiatry
especially affective disorders. In Groningen he is scientific coordinator for
the clinical studies in affective disorders and coordinator for the Groningen
site of the Netherlands Study on Depression and Anxiety (NESDA) a Dutch
multi-center 10 years follow-up study in patients with depressive and/or anxiety
disorders.
His major research interest is mood disorders, both
bipolar disorder and major depression, in which he is doing research on
epidemiology, etiology, long-term course and treatment. A main part of his
research has focused on the different pharmacological treatment options in
bipolar and unipolar mood disorders and their place in guidelines and
algorithms.
He has published over 260 papers, many of them in
international journals or as chapters in international books.
He has been member of the editorial board of the
Dutch Journal of Medicine (NTvG) and of the Dutch Journal of Psychiatry (TvP),
is currently member of the editorial board of Bipolar Disorders and has served
as editorial consultant for several international journals.
MICHAEL W. OTTO, PH.D.
Professor of Psychology
Boston University
Boston, Massachusetts
Dr. Otto specializes in the cognitive-behavioral
treatment of anxiety and mood disorders, and has developed clinical-research
programs for the treatment of panic disorder, posttraumatic stress disorder,
social phobia, bipolar disorder, psychotic disorders, substance dependence, and
medication discontinuation in patients with panic disorder. Dr. Otto's research
activities are closely tied to his clinical interests and target investigations
of the etiology and treatment of anxiety, mood, and substance-use disorders. Of
particular interest to Dr. Otto is the development and testing of new
treatments, including the combination of pharmacologic and cognitive-behavioral
strategies for treatment-refractory and substance abusing patients, and the
modification of treatment packages for novel populations (e.g., Cambodian
refugees). He has published over 190 articles, book chapters, and books
spanning these research interests. Dr. Otto is President-Elect for the
Association for Advancement of Behavior Therapy, a fellow of the American
Psychological Association, and a member of the Scientific Advisory Board for the
Anxiety Disorders Association of America. He also serves as a section editor
for Cognitive and Behavioral Practice, and on the editorial boards of Anxiety,
Behavior Research and Therapy, Clinical Psychology: Science and Practice,
Journal of Anxiety Disorders, Journal Watch in Psychiatry, and Psychotherapy and
Psychosomatics. Dr. Otto is a regular provider of continuing education and
continuing medical education workshops across the United States and abroad.
ATUL C. PANDE,
M.D., FRCPC
Vice-President, Neurosciences Development Leader
Pfizer Global Research & Development
Ann Arbor, Michigan, USA
Dr. Atul Pande received his degrees in medicine and
psychiatry from King George’s Medical College of the University of Lucknow in
India. He completed further training in clinical and research psychiatry at the
University of Western Ontario, Canada and the University of Michigan in the
United States. He joined the faculty of the University of Michigan Medical
School and successively directed the outpatient clinic and then the inpatient
unit of the Depression Program.
Dr. Pande joined Lilly Research Laboratories in 1992
and worked on the post-marketing development of Prozac. In 1994, he became
Director of Psychopharmacology Research at the Parke-Davis Pharmaceutical
Research Division of Warner-Lambert Company. He was promoted to Senior Director,
Psychiatric Research in 1996 and remained in that position until Warner-Lambert
merged with Pfizer Inc in 2000. In September 2000, he joined the Global Project
Management department of Pfizer Global Research & Development (PGRD), assuming
the position of Vice-President and Worldwide Portfolio Leader for CNS products.
In 2003, Dr. Pande moved to the position of
Development Leader for the Neurosciences in PGRD. He currently oversees
development of drugs for neurologic, psychiatric and pain conditions.
During his career in academic and industry research
Dr. Pande has published or presented over 150 original peer-reviewed scientific
papers, abstracts, letters and book reviews. He has presented his research at
national and international scientific meetings. He serves as a scientific
reviewer for several peer-reviewed journals in psychiatry. He has also been
awarded several patents.
Dr. Pande is certified as a specialist (Fellow) in
psychiatry by the Royal College of Physicians and Surgeons of Canada. He is a
fellow of the Collegium Internationale Neuro-Psychopharmacologicum, the Canadian
College of
Neuropsychopharmacology, and the American
Psychiatric Association.
SAGAR V.
PARIKH, M.D., FRCPC
Deputy Psychiatrist-in-Chief
University Health Network
Director of Continuing Medical Health Education
University of Toronto, Canada
Dr. Parikh is Deputy Psychiatrist-in-Chief at the
University Health Network (Toronto General Hospital, Toronto Western Hospital,
and Princess Margaret Hospital) and director of Continuing Mental Health
Education at the University of Toronto. He was formerly Head of the Division
of General Psychiatry at the University of Toronto, where he also serves as
associate professor of psychiatry. He served as Deputy Clinical Director of
Mood and Anxiety Program at the Centre for Addiction and Mental Health (Clarke
Institute), where he headed the Bipolar Clinic from 1994-2002, and where he
continues as Director of CME. Prior to psychiatry, he worked as a family
physician in northern Manitoba and southern Ontario.
Dr. Parikh is the author or editor of two books and
over sixty peer reviewed articles and book chapters. Current major studies
include a multi-site comparison of Psychoeducation versus Cognitive-Behavior
Therapy in Bipolar Disorder, and a study looking at Atypical Antipsychotics in
the Maintenance phase of BD, both funded by CIHR. His research has been funded
by the Canadian Institutes of Health Research, Canadian Psychiatric Research
Foundation, Ontario Mental Health Foundation, the Theodore and Vada Stanley
Foundation, the Ontario Ministry of Health, and other agencies. Research
interests include clinical treatments in mood disorders, health services
research, genetics, epidemiology, and educational research. He also is a
co-author of CANMAT treatment guidelines for Depression and for Bipolar
Disorder, served as co-chair of the CPA Schizophrenia Guidelines dissemination
project, and continues as Medical Editor for the CANMAT website. A prolific
speaker, he has presented over 250 CME events and been the course director for
over 50 programs. His teaching has won him local and international awards for
excellence, most recently the Canadian Psychiatric Association/COPCE Award for
Most Outstanding Continuing Education Activity in Psychiatry in Canada, in
2001.
MARY PHILLIPS, M.D.
Director
Section of Neuroscience and Emotion
Division of Psychological Medicine
Institute of Psychiatry
London, United Kingdom
Mary Phillips MD gained her medical degree from
Cambridge University, UK, and subsequently trained and qualified in psychiatry
at the Maudsley Hospital, London, UK. She received a Medical Research Council UK
(MRC) Clinical Training Fellowship, to examine visual scan paths in patients
with schizophrenia. She was awarded the equivalent of a PhD at the University of
Cambridge, UK for this work. Subsequently, the focus of her research has been
the application of functional brain imaging to the understanding of the neural
basis of emotion processing in health, and in individuals with psychiatric
disorders. Since, 2000, she has headed the Section of Neuroscience and Emotion,
Division of Psychological Medicine at the Institute of Psychiatry, London, and
in 2003, became Reader, and then Professor of Neuroscience and Emotion in
Psychiatry. In October, 2004, Dr. Phillips was appointed as Visiting Professor
of Psychiatry and Director of Functional Neuroimaging at the University of
Pittsburgh, Department of Psychiatry. In both of her laboratories, she directs
programs of research which aim to examine the way in which the normal human
brain responds to emotion, and how abnormalities in emotion processing may
contribute to the formation of symptoms in specific psychiatric populations. One
of the main aims of her research has been to define the persistent and disorder
specific abnormalities in pathophysiological processes underling emotion
processing in mood disorders, in particular, bipolar disorder. Dr. Phillips’
work has been internationally recognised . She has over 100 publications and
numerous invited talks in Europe, Canada, the US, and Japan.
KATE C. PRAVERA,
PH.D.
Executive Director
Child and Adolescent Bipolar Foundation
Wilmett, Illinois
Dr. Pravera assumed the post of executive director
of the Child and Adolescent Bipolar Foundation (CABF) in October 2004. CABF is a
parent-led, not-for-profit, Web-based membership organization of more than
28,000 families raising children diagnosed with, or at risk for, early-onset
bipolar disorder. As the mother of a 16 year-old daughter diagnosed with bipolar
disorder, she brings first hand experience with the challenges facing CABF’s
families.
Prior to joining CABF, Dr. Pravera was Senior
Fellow, Research Assistant Professor, and Director of Professional Educational
at the Great Cities Institute (GCI), University of Illinois at Chicago. GCI is a
campus-wide multi-disciplinary research institute promoting engaged research
with public sector, private and nonprofit institutions.
At UIC, Dr. Pravera launched the UIC Online
Certificate in Nonprofit Management Program, one of the first online learning
programs for nonprofit professionals in the country. Before joining the Great
Cities Institute, she served as founding executive director of the Chicago
Community Loan Fund. In that role, she oversaw the creation of a $4 million loan
pool for community reinvestment.
At CABF today, Dr. Pravera actively draws upon her
non-profit management expertise to ensure that the organization will achieve
maximum impact in its support of research, advocacy, education, and support of
parents raising children diagnosed with bipolar disorder.
Dr. Pravera earned her doctor of philosophy degree
from Northwestern University in Evanston, Illinois. Over the past 20 years, she
has taught at a number of colleges and universities, including: Spertus College
of Judaica, North Park College, Northwestern University, Truman College of
Chicago, Loyola University of Chicago, and the University of Illinois at
Chicago.
NOREEN A. REILLY-HARRINGTON, PH.D.
Instructor of Psychology
Harvard Medical School
Psychologist
Massachusetts General Hospital
Bipolar Clinic
Boston, Massachusetts
Dr. Reilly-Harrington is an Instructor in Psychology at Harvard Medical
School and is a Staff Psychologist at the Massachusetts General Hospital Bipolar
Clinic and Research Program. She specializes in the cognitive-behavioral
treatment of mood disorders and has lectured both nationally and internationally
on this topic. She is a Founding Fellow of the Academy of Cognitive Therapy and
recently co-authored “Bipolar Disorder: A Cognitive Therapy Approach” published
by the American Psychological Association. Dr. Reilly-Harrington is the Clinical
and Scientific Coordinator of the Psychosocial Pathway in the NIMH Systematic
Treatment Enhancement Program for Bipolar Disorder (STEP-BD) and is the
co-leader of the Cognitive-Behavioral intervention delivered in STEP-BD (the
largest study of bipolar disorder ever conducted). She has received research
awards from the Society for Research in Psychopathology, the Association for the
Advancement of Behavior Therapy, and Massachusetts General Hospital for her work
examining the role of life stress and cognition on the course of bipolar mood
disorders. Dr. Reilly-Harrington is also involved in studies examining
neuropsychological functioning in bipolar disorder, the application of
cognitive-behavioral treatment for rapid cycling bipolar disorder, and the use
of innovative technology to improve the reliability of rating scales used in
clinical trials.
LAURA ROBERTS, M.D.
Professor and Chair
Department of Psychiatry and Behavioral Science
Medical College of Wisconsin
Milwaukee, Wisconsin
Dr. Roberts serves as Professor and Chair in the
Department of Psychiatry and Behavioral Medicine at the Medical College of
Wisconsin. An NIH-funded career scientist with a special populations focus, Dr.
Roberts is a nationally recognized scholar and leader in ethics, psychiatry,
medicine, and medical education. She founded and directed the University of New
Mexico Health Sciences Center Institute for Ethics in 2002, where she was the
Jack and Donna Rust Professor of Biomedical Ethics. She created the
multidisciplinary research team, the Empirical Ethics Group at the University of
New Mexico School of Medicine in 1996. She is the Editor-in-Chief for the
journal Academic Psychiatry and serves as an editorial board member and peer
reviewer for many scientific journals. She is Past-President of the Association
for Academic Psychiatry and a member of the Scientific Advisory Council for the
National Institute for General Medical Sciences. Dr. Roberts has received
numerous teaching awards and has been an invited speaker for over 100
presentations, workshops and seminars. A dedicated writer, she has written
extensively on topics including clinical and research ethics, informed consent,
clinical medicine, educational scholarship, end-of-life care, physician and
medical student health care. Finally, Dr. Roberts has recently authored a book
for American Psychiatric Press, Incorporated entitled, Concise Guide to Ethics
in Mental Health Care and has a new edited book coming out this October,
Handbook of Career Development in Academic Psychiatry and Behavioral Sciences.
GARY S. SACHS, M.D.
Associate Professor in Psychiatry
Harvard Medical School
Director, Bipolar Mood Disorder Program
Massachusetts General Hospital
Gary S. Sachs, MD, is Associate Professor in
Psychiatry at Harvard Medical School; Clinical Assistant in Psychiatry and
Director, Bipolar Mood Disorder Program, at Massachusetts General Hospital;
Director, Bipolar Clinic and Research Program; and Director, Partners Bipolar
Treatment Center. Dr Sachs earned his medical degree at the University of
Maryland School of Medicine. He interned in family practice and psychiatry at
University of Maryland Hospital in Baltimore, was a resident in psychiatry and
Chief Resident, Acute Psychiatry Service, at Massachusetts General Hospital in
Boston.
Dr Sachs is the Principal Investigator of the NIMH
Systematic Treatment Enhancement Program for Bipolar disorder. He serves on the
scientific advisory board of the National Depression and Manic Depression
Association and is Co-editor-in-chief of Clinical Approaches to Bipolar Disorder
and on numerous editorial boards. Dr Sachs has authored over 150 articles,
abstracts, books, reviews, and book chapters.
IHSAM M.
SALLOUM, M.D., M.P.H.
Associate Professor of Psychiatry
University of Pittsburgh School of Medicine
Director of Research and Training, Addiction
Medicine Services
Western Psychiatric Institute and Clinic
Dr. Salloum received his medical training in Italy
at the University of Bologna School of Medicine, Bologna. He completed his
psychiatric residency at The University of Health Sciences/ The Chicago Medical
School in Chicago, Illinois. Since 1989 he has been on the faculty at the
University of Pittsburgh Medical School, in the Department of Psychiatry, where
he has held many positions including director of inpatients Dual Diagnosis Units
and medical director of the Drug and Alcohol Services, the Center for
Psychiatric and Chemical Dependency Services, and the Addiction Medicine
Services. Currently he is the director of research and training of the
Addiction Medicine Services of Western Psychiatric Institute and Clinic, one of
the nation’s largest private psychiatric hospitals.
Dr. Salloum has conducted extensive research into
the phenomenology and treatment of comorbid mood and alcoholism and other
addictive disorders. His work focused on elucidating the clinical
characteristics of psychiatric and substance use disorders comorbidities. He has
conducted extensive research into treatment of alcoholism and of alcoholism and
mood disorders comorbidity. A major focus of his treatment research is to
develop evidence-based effective treatment strategies for comorbid mood
disorders and alcoholism. Dr. Salloum was among the first to conduct
double-blind, placebo controlled studies in comorbid bipolar disorder and
alcoholism. His work also involves developing innovative psychotherapeutic
approaches for people with comorbid bipolar disorder and alcoholism. Dr.
Salloum lectures frequently on the topic of clinical comorbidities and treatment
of substance abuse with comorbid mod disorders.
Dr. Salloum has been the recipient of an Alcohol
Research Fellowship Award from the National Institute of Alcohol Abuse and
Alcoholism (NIAAA) and he has had several research project grants from the
National Institute of Alcohol Abuse and Alcoholism (NIAAA), the National
Institute on Drug Abuse (NIDA) and from industry. He has published extensively
on the subject of comorbidity. He is an editorial consultant for numerous
journals including the Archives of General Psychiatry, Bipolar Disorders, and
Biological Psychiatry. Dr. Salloum is an ad hoc reviewer for NIAAA and he is
also a consultant to the World Health Organization.
JAN SCOTT, M.D.,
FRCPsych
Professor of Psychological Treatments Research
Institute of Psychiatry
London, United Kingdom
Jan Scott is Professor of Psychological Treatments
Research at the Institute of Psychiatry, in London and a Visiting Professor at
the University of Newcastle upon Tyne. She is one of eight individuals worldwide
who was nominated as a Distinguished Founding Fellow of the Academy of Cognitive
Therapy. She trained in psychiatry in Newcastle upon Tyne and was a professor
there and in Glasgow before moving to London in 2002. Jan Scott has also held
visiting academic posts with Professor Aaron T Beck at UPenn in Philadelphia,
and Professor Eugene Paykel at Cambridge University in the UK, and she was also
awarded a travelling scholarship to Johns Hopkins University, Baltimore. Jan
Scott’s research focuses on combined treatment strategies (using pharmacotherapy
and psychotherapy) for individuals with difficult to treat mood disorders and
treatment resistant psychosis, and the investigation of the role of psychosocial
and cognitive factors in the onset and prognosis of severe mental disorders.
Professor Scott has over 250 publications on these topics, and her grant income
exceeds £4 million. She also plays an active role in training mental health
professionals in psychological therapies, leading national and international
workshops and training courses, and she has developed a number of brief
interventions (eg adherence therapy) for use in day-to-day clinical practice.
Professor Scott is a member of a number of national and international committees
and psychiatric journal editorial boards, for example, she is the vice-chair of
the MRC Neurosciences Board, an assistant editor of the British Journal of
Psychiatry, an immediate past president of the British Association of
Behavioural and Cognitive Psychotherapists, and an advisor to the Manic
Depression Fellowship.
GREGORY SIMON,
M.D., M.P.H.
Senior Investigator
Center for Health Studies, Group Health Cooperative
Seattle, WA
Dr. Simon received his MD degree from the University
of North Carolina followed by residency training in internal medicine at the
University of Washington, residency training in psychiatry at Massachusetts
General Hospital, and fellowship training in the Robert Wood Johnson Clinical
Scholars Program at the University of Washington. Since 1990 he has been an
investigator at the Center for Health Studies of Group Health Cooperative and
has practiced adult Psychiatry in Group Health’s Behavioral Health Service.
Dr. Simon’s research has focused on the epidemiology
and management of mood disorders in both primary care and psychiatric practice.
Specific research topics have included: epidemiology of mental disorders in
primary care, economic burden of mood and anxiety disorders, interventions to
improve depression management in primary care, cost-effectiveness of treatments
for mood disorders, effectiveness of psychotherapy for depression and bipolar
disorder, increasing access to evidence-based treatments, relative effectiveness
of different antidepressant and mood stabilizer drugs, and suicide risk in
depression and bipolar disorder.
Dr. Simon has published approximately 200 scientific
articles and book chapters, and serves on the editorial boards of several
psychiatric and general medical journals. He also serves on the national
scientific advisory board of the Depression and Bipolar Support Alliance. In
2004 he was the co-recipient of the DBSA’s Gerald Klerman Award for research.
Dr. continues to practice outpatient psychiatry
approximately half-time with a focus on treatment-resistant depression and
bipolar disorder.
NAOMI M. SIMON, M.D., MSC
Associate Director
Center for Anxiety and Traumatic Stress Related
Disorders
Massachusetts General Hospital
Boston, Massachusetts
Naomi M. Simon is Associate Director of the Center
for Anxiety and Traumatic Stress Related Disorders at Massachusetts General
Hospital in Boston, Massachusetts. Her clinical and research interests include
treatment approaches for refractory anxiety disorders, complicated grief, and
anxiety comorbidity with mood disorders. She has served as a principal
investigator or co-investigator on numerous studies examining the phenomenology
and treatment of panic disorder, generalized anxiety disorder, social anxiety
disorder, and post-traumatic stress disorder.
Dr. Simon is the recipient of a 5-year Career
Development Award from the National Institute of Mental Health (NIMH K23 1831)
to study pharmacologic and cognitive-behavioral treatment approaches to
treatment refractory panic disorder. She has also been participating in research
examining the impact of anxiety comorbidity for patients with bipolar disorder
as part of the National Institute of Mental Health Systematic Treatment
Enhancement Program for Bipolar Disorder (STEP-BD) study.
Dr. Simon earned her Medical Degree at Harvard
Medical School, and a Master’s in Epidemiology from the Harvard School of Public
Health in Boston. She completed an internship in Medicine and Psychiatry, and a
residency in Psychiatry at Columbia Presbyterian Hospital in New York, New York.
Dr. Simon is a member of several professional societies, such as the American
Psychiatric Association and serves on the Scientific Advisory Board of the
Anxiety Disorders Association of America. She has published over 35 journal
articles and book chapters.
EDWARD SCOLNICK,
M.D.
Director, Psychiatric Diseases Initiative
Broad Institute of MIT and Harvard
Cambridge, Massachusetts
Dr. Scolnick is currently an Associate Member of the
Broad Institute of MIT and Harvard and Director of the Broad’s Psychiatric
Diseases Initiative. From 1982 to 2003, Dr. Scolnick served in multiple
capacities as President, Merck Research Laboratories and Executive Vice
President for Science and Technology, Merck & Company, Inc; Executive Director
and Vice President, Department of Virus and Cell Biology, and Senior Vice
President, Basic Research, Merck Research Laboratories. Prior to joining Merck,
Dr. Scolnick worked at the National Cancer Institute where his work demonstrated
the cellular origin of sarcoma virus oncogenes in mammals and defined specific
genes that cause human cancer. He also worked at the National Heart Institute
where his work defined the stop signals in the genetic code and the biochemical
mechanism that produces the stops.
Dr. Scolnick was elected to the National Academy of
Sciences in 1984 and to the American Academy of Arts and Sciences in 1993. He
became a member of the Institute of Medicine in 1996 and served on the Board of
Directors of Merck & Co., Inc. from 1997 to 2002. He recently was selected as
Regents' Lecturer, University of California Berkeley, Frank H.T. Rhodes Class of
'56 University Professor at Cornell University, and appointed to the Board of
Visitors at the University of Pittsburgh School of Medicine. He currently serves
on the Board of Directors for Millipore Corporation and Renovis, Inc. and on the
Medical and Scientific Advisory Board for MPM Capital. He was also a Member of
the FDA Science Board from 2000 to 2002.
Dr. Scolnick's commitment to the mental health field
is evidenced by memberships on the Board of Directors for McLean Hospital and
the McGovern Institute for Brain Research. Prior to moving to the Broad
Institute, he was on the Board of Montgomery County Emergency Services and was
President of the Montgomery County Chapter of the National Alliance for the
Mentally Ill. From 1998 to 2002, he served as a member of the Council of the
National Institute of Mental Health. Dr. Scolnick holds an A.B. from Harvard
College and a M.D. from Harvard University Medical School.
TRISHA SUPPES,
M.D., Ph.D.
Associate Professor
Department of Psychiatry
Director, Bipolar Disorder Clinic and Research
Program
University of Texas Southwestern Medical Center
Dallas, Texas
Trisha Suppes, MD, PhD, is Associate Professor in
the Department of Psychiatry at the University of Texas Southwestern Medical
Center in Dallas. In addition, she is Director of the Bipolar Disorder Research
Program at the University of Texas Southwestern Medical Center and Committee
Chair for Updates on Texas Medication Algorithms.
Dr. Suppes earned her BA in Human Biology at
Stanford University in California, her PhD in Anatomy/Physiology at the
University of California at Los Angeles, and her MD at Dartmouth Medical School
in Hanover, New Hampshire. After graduating, she completed her residency in
Adult Psychiatry at McLean Hospital at Harvard Medical School in Belmont,
Massachusetts. Dr. Suppes conducted her postdoctoral fellowship in Neurology at
Stanford University School of Medicine and performed her Psychiatry clinical
fellowship at McLean. She also completed a fellowship in Neuroscience at Harvard
Medical School in Boston.
Dr. Suppes is a member of the Scientific Board of
the National Depressive and Manic-Depressive Association, the International
Society for Bipolar Disorders, the International Society for Affective
Disorders, and the National Institute of Health Advisory Council on STEP-BD
Women’s Studies. She is on the Biostatistics and Clinical Science Advisory
Committee at the University of Texas Southwestern Medical Center at Dallas. She
also sits on the Editorial Boards of Bipolar Disorders-an International Journal
of Psychiatry and Neurosciences, and Clinical Approaches in Bipolar Disorders.
In addition, she is an editorial reviewer for over a dozen peer-reviewed
journals, including the Archives of General Psychiatry, American Journal of
Psychiatry, Bipolar Disorders, Journal of Psychiatric Research, Journal of
Clinical Psychopharmacology, and Psychological Medicine.
Dr. Suppes’ research interests include long-term
treatment strategies for bipolar disorder, treatment strategies for bipolar II
disorder, use of treatment algorithms, and complementary medicine approaches to
treat patients with bipolar disorder. Her articles concerning these and related
topics are published in Archives of General Psychiatry, American Journal of
Psychiatry, Journal of Affective Disorder, Harvard Review of Psychiatry, Bipolar
Disorders and Journal of Clinical Psychiatry.
HOLLY A. SWARTZ, M.D.
Assistant Professor of Psychiatry
University of Pittsburgh School of Medicine
Depression and Manic-Depression Prevention Program
Western Psychiatric Institute and Clinic Pittsburgh, Pennsylvania
Dr. Swartz received a bachelor’s degree from
Harvard University in Cambridge, Massachusetts and her medical degree from the
Albert Einstein College of Medicine in the Bronx, New York. She completed her
psychiatric residency at Payne Whitney Clinic-New York Hospital in New York
City, and she joined the faculty of the Department of Psychiatry at the
University of Pittsburgh Medical School in 1997. She is currently an attending
psychiatrist at the Depression and Manic-Depression Prevention Program of
Western Psychiatric Institute and Clinic and a recipient of a Mentored
Patient-Oriented Research Career Development grant from the National Institute
of Mental Health.
Dr. Swartz’s research focuses on the development
and evaluation of psychosocial interventions for the treatment of mood disorder.
She is specifically interested in optimizing interventions for women with mood
disorders and adapting psychotherapies for difficult-to-treat populations. She
is currently conducting a trial of brief psychotherapy for depressed mothers
whose children also suffer from a psychiatric disorder. Dr. Swartz was a
co-investigator for the Maintenance Therapies in Bipolar Disorder study at the
University of Pittsburgh, and she is currently evaluating the role of
psychotherapy in the management of bipolar ll disorder.
DAWN O’DWYER TAYLOR,
PH.D.
Psychologist in Private Practice
Research Associate Department of Psychology
University of Colorado
Boulder, Colorado
Dr. Taylor received her Master’s in Experimental
Psychology and her Doctorate in Counseling Psychology from the Ohio State
University. Upon completion of her Doctorate in 1979, she moved to Boulder,
Colorado where she worked at the Boulder Mental Health Center until moving into
full-time private practice in 1986. She began working part-time with David
Miklowitz Ph.D. in his lab at the University of Colorado in 1991. Along with her
colleagues in the lab, she has studied the effectiveness of Focused Family
Therapy as a psychosocial treatment for adults and adolescents with bipolar
disorder. Her current special area of interest involves the developmental
pathways by which children come to be diagnosed as bipolar in adolescence.
MICHAEL E. THASE,
M.D.
Professor of Psychiatry
Department of Psychiatry
University of Pittsburgh Medical Center
Western Psychiatric Institute and Clinic
A Professor of Psychiatry at the University of
Pittsburgh Medical Center and the Western Psychiatric Institute and Clinic,
Michael E. Thase, M.D. is an active clinical investigator, whose research
focuses on the assessment and treatment of mood disorders, including the
correlates of differential response to various treatments for depression. A
1979 graduate of the Ohio State University College of Medicine, Dr. Thase has
directed the Mood Disorders Treatment and Research Program at Western
Psychiatric Institute and Clinic since its inception in 1987 and is now the
Chief of Adult Academic Psychiatry. A Distinguished Fellow of the American
Psychiatric Association, Dr. Thase has authored or co-authored over 400
scientific articles and book chapters, as well as 13 books. Dr. Thase remains
active in the community through numerous presentations regarding affective
disorders at state hospitals and seminars for the Office of Education and
Regional Programming, as well as for community hospitals.
MAURICIO TOHEN,
M.D., Dr.PH
Distinguished Lilly Scholar,
Lilly Research Laboratories
Indianapolis, Indiana, USA
Associate Clinical Professor of Psychiatry
McLean Hospital, Harvard Medical School
Boston, Massachusetts, USA
Mauricio Tohen, MD, DrPH, joined Lilly Research
Laboratories in Indianapolis, Indiana, USA in 1997, where he currently has the
title of Distinguished Lilly Scholar. He is also Associate Clinical Professor
of Psychiatry at McLean Hospital and Harvard Medical School in Boston,
Massachusetts, USA. From 1988 to 1997, he was Clinical Director of the Bipolar
and Psychotic Disorder Program at McLean Hospital.
Dr. Tohen received his MD from the National
University of Mexico and his Doctoral degree in Epidemiology from Harvard
University. His postdoctoral training included a residency in Psychiatry at the
University of Toronto, a clinical fellowship at McLean Hospital and Harvard
Medical School, and a teaching fellowship in Epidemiology at the Harvard School
of Public Health.
Dr. Tohen received a National Service Award in
Psychiatric Epidemiology from the National Institute of Mental Health (NIMH) and
Harvard University. He also received a FIRST award from NIMH, the Pope Award
from McLean Hospital, and a NARSAD Young Investigator Award. He has served on
the Epidemiology and Genetics and the Clinical Centers and Special Projects
Review committees at NIMH. Dr. Tohen’s research, supported by grants from NIMH
and the pharmaceutical industry, has focused on the epidemiology, outcome, and
treatment of bipolar disorder.
Dr. Tohen has contributed more than 140 original
publications. He coedited two books, Psychiatric Epidemiology (1995 first
edition, 2002 second edition) and Mood Disorders Across the Life Span (1996). He
also edited the book Comorbidity in Affective Disorders (1999).
EDUARD VIETA,
M.D., PH.D.
Professor of Psychiatry
Director, Bipolar Disorders Clinic
Director of Research, Clinical Institute of
Neuroscience
University of Barcelona, Spain
Eduard Vieta is professor of Psychiatry and the
director of the Bipolar Disorders Program of the Hospital Clinic at the
University of Barcelona, Barcelona, Spain. He also serves as director of
Research at the Clinical Institute of Neuroscience at the same institution.
Prof. Vieta’s research focuses on the neurobiology and treatment of bipolar
disorder. His program has leaded many of the research in the area of novel
treatments, both pharmachological and psychological, including atypical
antipsychotic, novel antiepileptic drugs and psychoeducation. Since 2001, his
research programme has been awarded by the Stanley Medical Research Institute,
Bethesda, Maryland, USA. He has authored more than 100 original articles, 30
book chapters and 16 books on bipolar disorder, and he reviews articles for more
than 20 international scientific journals.
ADELE C. VIGUERA, M.D.
Assistant Professor of Psychiatry
Harvard Medical School
Associate Director of the Perinatal and Reproductive
Psychiatry Program
Massachusetts General Hospital, Boston, MA
Adele C. Viguera, M.D., is the associate director of
the Perinatal and Reproductive Psychiatry Program at Massachusetts General
Hospital and an Assistant Professor of Psychiatry at Harvard Medical School in
Boston, Massachusetts. Dr. Viguera received her MD from Dartmouth Medical School
in Hanover, New Hampshire, and served her internship and residency at
Massachusetts General Hospital and McLean Hospital in Belmont, Massachusetts.
The recipient of several honors and awards, Dr.
Viguera is a recipient of an NIMH sponsored K23 Mentored Patient-Oriented
Research Career Development Award as well as a NARSAD Young Investigators Award
for her project on neonatal outcome and devlopment following exposure to
lithium. Her current research interests include the course and treatment of
bipolar mood disorders during pregnancy and the postpartum period and the
effects of prenatal lithium exposure on infant development. She served on the
expert consensuspanel for the formulation of treatment guidelines for women with
bipolar disorder during pregnancy and the postpartum period which was published
in 2004 in the American Journal of Psychiatry. In addition, Dr. Viguera and Dr.
Jeff Newport are recent recipients of a collaborative R01 grant which will
examine pharmacologic and clinical predictors of relapse among bipolar women
during pregnancy.
Dr. Viguera’s research, teaching and clinical
activities focus on women’s mental health, specifically psychiatric disorders
across the female reproductive life-cycle. Dr. Viguera’s additional clinical
activities include outpatient evaluation, consultation and clinical follow-up in
both the Perinatal & Reproductive Psychiatry Program and the Obstetrics and
Gynecology Outpatient Department at the Massachusetts General Hospital. She
performs diagnostic and psychopharmacologic consultation on pregnant and
postpartum women with major mood disorders. Her work has been published in a
number of scientific journals and books.
ROBERT M.
WETTSTEIN, M.D.
Clinical Professor of Psychiatry
University of Pittsburgh School of Medicine
Pittsburgh, PA
Dr. Wettstein is in the private practice of
psychiatry, with an emphasis on legal and ethical practice issues. He is a
consultant to the state licensing boards in medicine, psychology, nursing,
dentistry, chiropractic, and law, and evaluates impaired professionals. He also
conducts independent examinations regarding disability, workers compensation,
and criminal responsibility.
Between 1984 and 1996, Dr. Wettstein was on the
full-time faculty at WPIC, and was codirector of the Law and Psychiatry
Program. He was involved in clinical consultations, treatment, and research
activities in the law and psychiatry area. In 1996, he was awarded the “Golden
Apple” award for excellence in teaching by the residents at WPIC.
Dr. Wettstein was Editor of the quarterly journal
Behavioral Sciences and the Law until 1996. He is coauthor with Barbara Weiner,
Esq. of Legal Issues in Mental Health Care. His edited volume, Treatment of
Offenders with Mental Disorders, was published in 1998. He is also author of
many other publications on legal and ethical issues in mental health care.
He is the past President of the American Academy of
Psychiatry and the Law.
KATHERINE
L. WISNER, M.D., M.S.
Professor
Psychiatry, Obstetrics and Gynecology, Epidemiology
and Women Studies
University of Pittsburgh
Director, Women’s Behavioral HealthCARE
Western Psychiatric Institute and Clinic
Pittsburgh, Pennsylvania
Katherine L. Wisner, M.D., M.S., is Professor of
Psychiatry, Obstetrics and Gynecology and Reproductive Sciences, Epidemiology,
and Women’s Studies. She is also Director of Women’s Behavioral HealthCARE, at
the Western Psychiatric Institute and Clinic, University Pittsburgh School of
Medicine. Dr. Wisner’s main focus is research related to the psychiatric
treatment of women of childbearing age. She is recognized as an expert in the
treatment of depression during pregnancy and the postpartum period, is widely
published, and lectures nationally and internationally. She is a member of the
Surgeon General’s Advisory Group for Mental Health and Women Project. Dr.
Wisner completed the Executive Leadership in Academic Medicine program and
served as the President of women faculty at Case Western Reserve University
School of Medicine. She is a Distinguished Member of the American Psychiatric
Association. Dr. Wisner is a member of the Committee on Research on Psychiatric
Treatments of the APA, the Committee to Define Research to Inform DSM-V, and the
FDA Committee on the Revision of the Classification System for Drug Use During
Pregnancy and Lactation. She has served on numerous NIMH study sections for the
review of grants, and was a founding member of the Data Safety and Monitoring
Board for multi-site studies.
Dr. Wisner feels that her greatest qualification for
her work is being the mother of two industrious daughters! Dr. Wisner is an
avid gardener, has cats, dogs, birds, rabbits, owns horses and rides dressage.
LAKSHMI N. YATHAM,
MBBS, FRCPC, MRCPsych
Michael Smith Foundation senior Scholar
Professor of Psychiatry,
Director, Mood Disorders
Clinical Research Unit
University of British Columbia
Vancouver, British Columbia, Canada
Lakshmi N. Yatham, MBBS, FRCPC, MRCPsych (UK), is
Professor of Psychiatry and Director of the Mood Disorders Clinical Research
Unit at the University of British Columbia in Vancouver. His major areas of
research interest include neurobiology and treatment of bipolar disorder and
major depression. Dr. Yatham is a recipient of the Michael Smith Foundation
Senior Scholar Award, and his work has been funded by a number of peer-reviewed
funding agencies such as the Canadian Institutes of Health Research (CIHR),
Canadian Psychiatric Research Foundation, Stanley Foundation, and National
Alliance for Research on Schizophrenia and Depression, USA. Dr. Yatham leads a
Canadian consortium on bipolar disorder, which is currently pursuing development
and testing of new and innovative treatments for bipolar disorder under his
direction with substantial funding from CIHR.
Dr. Yatham co-led the development of Canadian
guidelines for treatment of bipolar disorder in 1997 and his group recently
revised those guidelines for 2005 and these will be published in Bipolar
Disorders Journal in June. He is Chair of the bipolar group of the Canadian
Network for Mood and Anxiety Treatments (CANMAT), and is actively involved at a
national and international level in continuing medical education and public
education on diagnosis and treatment of bipolar disorder for psychiatrists,
family physicians, and the general public. Dr. Yatham is the Vice-President for
the International Society for Bipolar Disorders and he is on the editorial
boards of a number of journals including Bipolar Disorders, Brain Pharmacology,
Human Psychopharmacology, Quarterly Journal of Mental Health etc. He has
published over 130 papers in peer-reviewed international journals and presented
his research work at numerous international conferences.
Bios A-L
Top of Page
|
|
|
